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Abstract 
Purpose: 
Multicentric carpal tarsal osteolysis (MCTO) is a rare skeletal disease with progressive osteolysis at the 
carpal and tarsal bones. Zankl A et al., defined an autosomal missense mutation in the transactivation domain of 
transcription factor MAFB as the cause of MCTO, which is also reported to be highly expressed in osteoclasts. 
However, there is no definite treatment for MCTO today since the relationship between MafB and osteoclasts in 
vivo remains unknown. Previous studies show that MafB is highly expressed in myeloid cells including osteoclasts 
and that MafB negatively regulates osteoclastogenesis in vitro. Therefore, it was predicted that MCTO occurs 
from the loss of MAFB function, which causes upregulation of osteoclast differentiation. However, the function 
of MafB in osteoclastogenesis in vivo is not clarified till this day. Thus, function of MafB in osteoclastogenesis 
in vivo needs more clarification using animal models for a better understanding and develop a treatment against 
MCTO. The aim of this study is to clarify the function of MafB in osteoclast differentiation and cause a break-
through in the treatment of MCTO. 
 
Materials and Methods:  
Myeloid specific Mafb knock-out mice (Mafbf/f::LysM-Cre) were used in this study to examine the 
function of MafB in osteoclasts. The effect of osteoclatogenesis against the bone phenotypes of these mice were 
examined by measuring the bone density of Mafbf/f::LysM-Cre mice at 8 weeks using micro-CT analysis. In 
addition, resistance against age-related osteoporosis and RANKL-induced bone loss was also analyzed using 
micro-CT analysis. Osteoclatogenesis ability of the bone marrow cells of Mafbf/f::LysM-Cre mice was measured 
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by primary osteoclast differentiation assay and pit assay. Moreover, RNA-sequencing was conducted to analyze 
the candidate pathways that MafB could be regulating during osteoclast differentiation. Following these findings, 
mouse harboring the human MCTO mutation (MafbMCTO/MCTO) was generated using the CRISPR-Cas9 system to 
relate our findings from Mafbf/f::LysM-Cre mice to the pathology. Bone phenotype of femurs and tarsal bones 
was analyzed through micro-CT. To analyze the effect of MCTO on the MafB protein itself, transactivation level 
of MCTO mutated MafB was measured using luciferase assay against known MafB target promoters. Finally, 
MCTO mutation was related to osteoclastogenesis ability of MafbMCTO/MCTO mice, by primary osteoclast 
differentiation assay using bone marrow cells of  MafbMCTO/MCTO mice. 
 
Results:  
Micro-CT analysis of the femur bone of Mafbf/f::LysM-Cre mice showed an increase in bone density 
compared to control, indicating that MafB promotes osteoclast differentiation in vivo. This was further confirmed 
by Mafbf/f::LysM-Cre mice exhibiting resistance against osteoclast driven bone resorption. Culturing osteoclasts 
from bone marrow cells of Mafbf/f::LysM-Cre mice showed lower numbers of multinucleated cells compared to 
control, especially at 42 hours after RANKL-induction. To identify the pathway that MafB regulates in 
osteoclastogesis, RNA-sequencing was performed against Mafbf/f::LysM-Cre mice derived osteoclasts at 42 hours 
after RANKL-induction. Osteoclast inhibitory genes and markers of other immune cells including macrophages, 
were up-regulated in Mafbf/f::LysM-Cre mice derived osteoclasts. From this, it was predicted that MafB promotes 
osteolastogenesis by fine tuning osteoclast precursors to the osteoclast linage. However, the results obtained from 
Mafbf/f::LysM-Cre mice contradicts to the symptoms of MCTO patients. Therefore, the bone phenotypes of 
MafbMCTO/MCTO mice were analysed though micro-CT. The bone density of femur bones and tarsal bone volume 
was comparable between control and MafbMCTO/MCTO mice at 2 weeks. However, both femur bone density and 
tarsal bone volume were significantly lower in  MafbMCTO/MCTO mice by 8 weeks. The function of MCTO mutated 
MafB were also examined by luciferase assay against reported target genes of MafB, where MCTO mutated MafB 
increased transcriptional ability compared to MafB containing the intact protein sequence. From the in vivo 
phenotype of  MafbMCTO/MCTO mice, it was suggested MafbMCTO/MCTO mice increases osteoclast differentiation. 
Therefore, osteoclast differentiation was assessed using primary osteoclast differentiation assay using 
MafbMCTO/MCTO mice derived cells. As a result, MafbMCTO/MCTO mice showed increased multinucleated cell number 
compared to control, suggesting that MCTO occurs from hyper-differentiation of osteoclasts. 
 
Discussion: 
  Tis study, demonstrates the function of MafB in osteoclastogenesis in vivo for the first time. These 
include; MafB promotes the differentiation of osteoclasts and MCTO mutation activates transcriptional function 
of MafB, and MCTO is caused by over-differentiating osteoclasts. These were shown by  Mafbf/f::LysM-Cre 
mice being resistance against osteoclast driven bone resorption and primary osteoclast differentiation experiments 
showing lower multinucleated osteoclasts. RNA-sequencing results also revealed an “identity crisis” of osteoclast 
progenitors from Mafbf/f::LysM-Cre mice at 42 hours post culture. These results suggest that MafB regulates 
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osteoclastogenesis at later stages of differentiation by priming osteoclast progenitors to the osteoclast linage. 
Although previous studies demonstrate that MafB works as a negative regulator against osteoclastogenesis, they 
also mention that MafB expression gradually increases its expression after RANKL induction. In contrast, this 
study may be focusing on the MafB function at later stages of osteoclastogenesis, which acts as a positive regulator 
rather than an inhibitor. Therefore, the combination of the study of MafB as an inhibitor of osteoclatogenesis and 
the current study can provide valuable information to the whole picture of MafB in osteoclast differentiation. 
 
In order to relate the findings from the Mafbf/f::LysM-Cre mice to MCTO, bone phenotypes of MafbMCTO/MCTO 
mice were analyzed in a time course manner. The bone density of femur bones and tarsal bone volume was 
comparable between control and MafbMCTO/MCTO mice at 2 weeks. However, by 8 weeks there were less femur 
bone density and tarsal bone volume in MafbMCTO/MCTO mice. These results suggest that MCTO onsets between 2 
weeks and 8 week-of-age. 
Since the in vivo bone phenotypes of MafbMCTO/MCTO mice presented osteolysis-like phenotype, the 
transactivation function of MCTO-mutated MafB was examined. Luciferase assay results against MafB target 
promoters showed that transactivation function increases in MCTO-mutated MafB. These results indicate that 
MCTO mutation on MafB also promotes osteoclastogenesis, since Mafb-depletion inhibited osteoclastogenesis 
in Mafbf/f::LysM-Cre mice. Primary osteoclast differentiation assay using MafbMCTO/MCTO mice derived cells 
supported this hypothesis, where multinucleated osteoclast number were increased in cultures of MafbMCTO/MCTO 
mice derived cells. These results suggest that MCTO happens from increased MafB function, which in turn causes 
osteoclast hyper-activity. Although these results show that MCTO could happen from osteoclast differentiation, 
the direct contribution of osteoclasts to MCTO in vivo remains to be answered. Therefore, more investigation 
through histological examination and rescue experiment using bisphosphonate at the timing of onset must be 
conducted to truly validate our hypothesis. 
 
Over all, the present study states that MafB holds another function other than inhibiting 
osteoclastogenesis, and that MCTO occurs from promoted osteoclast differentiation. These findings may facilitte 
the progression of drug development that targets osteoclasts in MCTO patients 
 
 
 
 
 
